The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
NICE has today published final draft guidance recommending bevacizumab with chemotherapy for people with metastatic colorectal cancer. This is the first time NICE has been able to recommend ...
Atezolizumab plus bevacizumab and chemotherapy did not significantly improve PFS compared with placebo (6.4 vs 6.7 months) in patients with advanced ovarian cancer. Atezolizumab in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback